Alissa Huston

Summary

Affiliation: University of Pittsburgh
Country: USA

Publications

  1. ncbi request reprint Role of the microenvironment in multiple myeloma bone disease
    Alissa Huston
    University of Pittsburgh Cancer Institute, and VA Pittsburgh Healthcare System, Research and Development, PA 15240, USA
    Future Oncol 2:371-8. 2006
  2. ncbi request reprint Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma
    Lanie K Francis
    University of Pittsburgh Cancer Institute, Division of Hematology Oncology, Department of Internal Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 12:6826-35. 2006
  3. ncbi request reprint Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    Alissa Huston
    Exp Hematol 34:1616. 2006
  4. doi request reprint Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment
    Alissa Huston
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York, USA
    Clin Cancer Res 14:865-74. 2008
  5. doi request reprint Involvement of hepcidin in the anemia of multiple myeloma
    Sanjai Sharma
    West Los Angeles VA University of California Los Angeles Medical Center, Los Angeles, CA 90073, USA
    Clin Cancer Res 14:3262-7. 2008

Collaborators

Detail Information

Publications5

  1. ncbi request reprint Role of the microenvironment in multiple myeloma bone disease
    Alissa Huston
    University of Pittsburgh Cancer Institute, and VA Pittsburgh Healthcare System, Research and Development, PA 15240, USA
    Future Oncol 2:371-8. 2006
    ....
  2. ncbi request reprint Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma
    Lanie K Francis
    University of Pittsburgh Cancer Institute, Division of Hematology Oncology, Department of Internal Medicine, Pittsburgh, Pennsylvania, USA
    Clin Cancer Res 12:6826-35. 2006
    ..Our objective was to determine the effects of the mTOR inhibitor rapamycin and the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on multiple myeloma cells...
  3. ncbi request reprint Tumor lysis syndrome following thalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
    Alissa Huston
    Exp Hematol 34:1616. 2006
  4. doi request reprint Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment
    Alissa Huston
    James P Wilmot Cancer Center, University of Rochester, Rochester, New York, USA
    Clin Cancer Res 14:865-74. 2008
    ....
  5. doi request reprint Involvement of hepcidin in the anemia of multiple myeloma
    Sanjai Sharma
    West Los Angeles VA University of California Los Angeles Medical Center, Los Angeles, CA 90073, USA
    Clin Cancer Res 14:3262-7. 2008
    ..Because interleukin (IL)-6 is a potent inducer of hepcidin expression and its levels are elevated in multiple myeloma, we studied the role of hepcidin in the anemia of multiple myeloma...